The addition of blinatumomab to Interfant-06 chemotherapy appeared safe for infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia, according to data published in The New England Journal of Medicine.
The combination of the immunotherapy and chemotherapy also resulted in improved minimum residual disease response, as well as higher short-term DFS and OS rates, results of the prospective, multicenter phase 2 study showed.
“It was great to see that after decades without improvement in outcome despite intensifying chemotherapy, adding only one course of blinatumomab